Topical Application of Tazarotene in the Treatment of Nonerythrodermic Lamellar Ichthyosis

Stege, Helger; Hofmann, Benedikt; Ruzicka, Thomas; Lehmann, Percy

doi:10.1001/archderm.134.5.640

Cited by 28 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Its molecular structure was engineered in such a way as to be selective for the RAR class of nuclear receptors over RXR, to activate RARb and RARg preferentially over RARa and to possess clinically favorable pharmacokinetic properties. Tazarotene, initially used to treat cutaneous hyperproliferative conditions such as psoriasis (Marks, 1999) and ichtiosis (Stege et al, 1998;Hofmann et al, 1999), has subsequently been used with success in the topical treatment of basal cell carcinomas (BCC) (Peris et al, 1999). The molecular mechanisms underlying the effectiveness of this retinoid as anti-tumoral agent are unknown and are thought to rely on its ability to modulate the expression of a specific subset of genes leading to cell-cycle arrest, differentiation, or apoptosis.…”

mentioning

confidence: 99%

The p73 Gene Is an Anti-Tumoral Target of the RARβ/γ-Selective Retinoid Tazarotene

Papoutsaki

Lanza

Marinari

et al. 2004

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Tazarotene, a member of the new class of acetylenic retinoids, has been shown to be effective in the treatment of several hyperproliferative skin diseases, including non-melanoma skin cancer. Its effectiveness is thought to rely on the ability to activate retinoic acid receptors beta and gamma and to induce a number of downstream anti-proliferative genes. Here, we show that the p53-related gene p73 is a target of tazarotene. Indeed, tazarotene modulates the expression of the p73 gene in immortalized keratinocyte cell lines by inducing the pro-apoptotic and anti-proliferative TAp73 isoforms and by repressing the anti-apoptotic and pro-proliferative DeltaNp73 isoforms. This occurs at the transcriptional level through a coordinated action on P1p73 and P2p73 promoters that control the expression of TA and DeltaN isoforms, respectively. The selective downregulation of DeltaNp73 expression by small interfering RNA led to an enhancement of tazarotene-induced bax activation and apoptosis, whereas the downregulation of both TA and DeltaN isoforms impairs tazarotene-mediated apoptosis. These results indicate the relevance of p73 gene products in tazarotene-induced growth inhibition and effectiveness in the treatment of skin tumors.

show abstract

mentioning

confidence: 99%

The p73 Gene Is an Anti-Tumoral Target of the RARβ/γ-Selective Retinoid Tazarotene

Papoutsaki

Lanza

Marinari

et al. 2004

Journal of Investigative Dermatology

View full text Add to dashboard Cite

show abstract

“…Only occasionally is rctinoid therapy indicated (sec below). Apart from emollients and keratolytic agents, topical applications of more specific drugs, such as tazarotene (39), N-acetylcysteine (40. 41), liarozole (see below) and calcipotriol (42)(43)(44) have also been tried in LI and EHK with variable success (Table VI).…”

Section: Treatment Of Severe Disease (As In Lamellar Ichthyosis and Ementioning

confidence: 99%

Congenital Ichthyosis: An Overview of Current and Emerging Therapies

Vahlquist

Gånemo²,

Virtanen³

2008

Acta Derm Venereol

115

105

View full text Add to dashboard Cite

Congenital ichthyosis is a collective name for a group of monogenetic disorders of cornification, sometimes associated with systemic symptoms. There may be an abnormal quality or quantity of scale produced, abnormal thickness of stratum corneum or abnormal keratinocyte kinetics, often associated with skin inflammation. Pruritus, skin fragility, ectropion and anhidrosis are sometimes associated with the rare types of ichthyosis. Three important mechanisms are involved in the action of topical agents used in the treatment of ichthyosis: hydration, lubrication and keratolysis. The latter effect can also be achieved with systemic retinoids. For ichthyosis with an increased tendency towards skin infections, antimicrobials are another group of widely used agents. Considering that patients with ichthyosis are potential mega-users of topical therapy, with an estimated lifetime consumption of approximately one tonne cream per capita, surprisingly few controlled trials of the various treatments have been performed. Moreover, nearly all therapeutic principles were established long before the recent increase in knowledge about the aetiology and pathophysiology of ichthyosis. This calls for new ideas and intensified efforts to develop future ichthyosis therapies.

show abstract

“…1 Topical retinoids such as tazarotene have been shown to be effective in ichthyoses when applied over 3 weeks to 5 months. [2][3][4] The purpose of this study was to assess the risk of systemic absorption of tazarotene in children with ichthyoses.…”

Section: Treatment Of Ichthyosiform Diseases With Topically Applied Tmentioning

confidence: 99%

Treatment of ichthyosiform diseases with topically applied tazarotene: Risk of systemic absorption

Nguyen

Cunningham

Eichenfield

et al. 2007

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Topical Application of Tazarotene in the Treatment of Nonerythrodermic Lamellar Ichthyosis

Cited by 28 publications

References 6 publications

The p73 Gene Is an Anti-Tumoral Target of the RARβ/γ-Selective Retinoid Tazarotene

The p73 Gene Is an Anti-Tumoral Target of the RARβ/γ-Selective Retinoid Tazarotene

Congenital Ichthyosis: An Overview of Current and Emerging Therapies

Treatment of ichthyosiform diseases with topically applied tazarotene: Risk of systemic absorption

Contact Info

Product

Resources

About